BioChain announces expanded line of NGS characterized bio-samples for oncology researchers

NEWARK, Calif.: NEWARK, Calif., Sept. 22, 2021 /PRNewswire/ -- BioChain Institute, ("BioChain"), a leader in high quality processed bio-sample products, announced an expanded line of Next Generation Sequencing (NGS) characterized bio-samples encompassing a variety of cancer-related mutations available for preclinical drug development and as reference samples for CLIA labs. "Scientists...

Click to view original post